---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-096269"
form_type: "8-K"
ticker: "CTOR"
cik: "0001851484"
company_name: "CITIUS ONCOLOGY, INC."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:14:13.331111+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Citius Oncology reports 27% ORR, 33% CBR in Phase I trial of LYMPHIR + pembrolizumab for recurrent solid tumors

## Summary
- 27% objective response rate (4/15 evaluable) and 33% clinical benefit rate (5/15) in heavily pre-treated gynecologic tumors.
- Median progression-free survival of 57 weeks (range 30-96 weeks) for patients achieving clinical benefit.
- Combination was well-tolerated with no documented ≥Grade 3 immune-related adverse events; one dose-limiting toxicity (capillary leak) at 12 mcg/kg.
- Two of four partial responders had failed prior anti-PD-1 therapy, suggesting potential to overcome checkpoint resistance.
- Trial nearing completion with three additional patients to enroll; data presented at SITC 2024.

## SEC filing metadata
- accession: 0001213900-24-096269
- form_type: 8-K
- ticker: CTOR
- cik: 0001851484
- company_name: CITIUS ONCOLOGY, INC.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851484/000121390024096269/0001213900-24-096269-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851484/000121390024096269/ea0220666-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-096269
- JSON: https://secwatch.observer/filing/0001213900-24-096269.json
- Plain text: https://secwatch.observer/filing/0001213900-24-096269.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.